We are pleased to announce the successful closing of a multi-asset secondary transaction whereby StepStone Group has provided a liquidity solution to existing investors in a transaction involving dss+ and Essential Pharma. StepStone solely capitalized the transaction on the back of the single-asset continuation vehicle established for Essential Pharma, re-affirming Gyrus Capital’s commitment to support the long-term growth strategy of both dss+ and Essential Pharma. For more information https://gyrus.info/4gctZQ6
Gyrus Capital
Wagniskapital- und Private-Equity-Auftraggeber
Cité, Geneva 2.767 Follower:innen
Sector-focused transformational investments
Info
Gyrus is a private equity firm dedicated to transformational investments. We focus on sectors with strong, sustainable growth and investment opportunities where we can leverage our sector focus to support management to drive change and unlock value. Gyrus is based in Geneva, Switzerland.
- Website
-
http://www.gyruscapital.com
Externer Link zu Gyrus Capital
- Branche
- Wagniskapital- und Private-Equity-Auftraggeber
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Cité, Geneva
- Art
- Privatunternehmen
Orte
-
Primär
Wegbeschreibung
Quai du Mont-Blanc 1
Cité, Geneva 1201, CH
Beschäftigte von Gyrus Capital
Updates
-
Gyrus Capital hat dies direkt geteilt
Gyrus Capital is delighted to announce the successful closing of a €600M continuation vehicle for Essential Pharma, led by AlpInvest Partners and supported by StepStone Group and a high-quality syndicate of investors. Since acquiring Essential Pharma in 2019, Gyrus has worked closely with its leadership team to transform the company into a global specialty pharma group, addressing critical patient needs across niche and rare disease therapeutic areas. This transaction represents a major milestone for Essential Pharma and will provide the necessary resources to further expand and continue its mission of ensuring access to life-changing treatments for patients worldwide. For more information: https://gyrus.info/41wnAe1
-
We are delighted to announce the recapitalisation of Essential Pharma and the successful closing of a single-asset continuation fund. The transaction represents a major milestone for Essential Pharma and will provide the necessary resources to further expand and continue its mission of ensuring access to life-changing treatments for patients worldwide.
Today marks a significant milestone for Essential Pharma as we announce the completion of a €900 million recapitalisation, marking a new chapter in our growth journey. This investment will fuel our continued expansion, enabling us to build on our diversified portfolio and late-stage pipeline in established and rare disease medicines, and strengthens our ability to ensure patient access to essential medicines in new and existing markets worldwide. We're excited to continue working with Gyrus Capital, whose shared vision and support has been instrumental to our continued growth as a leading international specialty pharma group. Together, we look forward to furthering our commitment to addressing unmet medical needs and strengthening our mission to deliver essential medicines to patients who depend on us. Find out more here: https://lnkd.in/epYtwVG8 #Fundraise #EssentialPharma #PharmaTeam
-
-
Gyrus Capital is delighted to announce the successful closing of a €600M continuation vehicle for Essential Pharma, led by AlpInvest Partners and supported by StepStone Group and a high-quality syndicate of investors. Since acquiring Essential Pharma in 2019, Gyrus has worked closely with its leadership team to transform the company into a global specialty pharma group, addressing critical patient needs across niche and rare disease therapeutic areas. This transaction represents a major milestone for Essential Pharma and will provide the necessary resources to further expand and continue its mission of ensuring access to life-changing treatments for patients worldwide. For more information: https://gyrus.info/41wnAe1
-
🔔 We’re expanding our team at Gyrus Capital We’re pleased to welcome Luigi Dufour and Bianca Bonetti to our executive team as we continue to grow in the #healthcare and #sustainability sectors. Their extensive backgrounds in private equity, innovation, and strategic planning will be invaluable as we focus on corporate carve-outs in the €50-500 million segment. These additions mark a key moment for Gyrus as we strengthen our capabilities, particularly in #Italy, and continue driving our strategic initiatives forward. #GyrusCapital #Healthcare #Sustainability #TeamExpansion #StrategicGrowth
-
-
We are delighted to announce that the Gyrus Capital Fund II has invested in Neo Medical, a pioneering Swiss technology company in spine surgery. We are excited to support Neo Medical’s vision for growth.
𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚: 𝗡𝗲𝗼 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗦𝗲𝗰𝘂𝗿𝗲𝘀 𝗟𝗮𝗻𝗱𝗺𝗮𝗿𝗸 𝗘𝗾𝘂𝗶𝘁𝘆 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 $𝟲𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝘁𝗼 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗚𝗹𝗼𝗯𝗮𝗹 𝗚𝗿𝗼𝘄𝘁𝗵 𝗶𝗻 𝗦𝗽𝗶𝗻𝗲 𝗦𝘂𝗿𝗴𝗲𝗿𝘆 Led by Gyrus Capital SA, alongside the participation of existing investors, including founders Vincent Lefauconnier and Jonas Larsson, this landmark round is one of the most significant in the spine industry in the last decade. Neo CEO, Vincent Lefauconnier, said: “This funding will enable us to grow and push the boundaries of what is possible in spine surgery, bringing our solutions to more healthcare providers and, most importantly, improving outcomes for patients.” “Neo Medical’s vision and product platform has already proven itself in Europe and is poised to expand rapidly in the US,” said Dr. Robert Watson, Partner and Co-Founder of Gyrus. “We are excited to partner with the management team and support Neo’s vision in redefining patient care.” Read the full press release here: https://lnkd.in/dqv-jbZa Take the next step in spine surgery. #Raise #FundingRound #NextGenTech #BreakingNews
-
dss⁺ announced today the acquisition of Infrata, a leading global #infrastructure advisory firm. With the addition of Infrata, dss⁺ expands its capabilities in technical, commercial and demand advisory services for lenders, investors and sponsors of infrastructure projects worldwide. Founded in 2011, Infrata adds deep technical expertise within #transportation, including roads, airports, ports, waterways, and railways. The services provided by Infrata reinforce the dss⁺ operational consulting value proposition to address macro trends in population growth, #energytransition and efficient infrastructure project execution. https://lnkd.in/dFNKtbWQ
-
Gyrus is delighted to welcome Dr Klaus Lun as the new CEO of LRE Medical. He brings over 20 years of experience in the life sciences, biotech and diagnostics industries. We look forward to him joining the LRE team in November. To learn more, visit https://gyrus.info/4f0K1fH
-
-
Congratulations dss+ on being named one of the best managed businesses in Switzerland!
dss⁺ has been 🏆 named as one of the Best Managed Companies in Switzerland. This award was sponsored by Deloitte, Julius Baer, SIX Swiss Exchange and assigned by an independent jury. This award has been given to us due to our purpose of saving lives and building a sustainable future, our quality of work and dedication to our clients, our culture and entrepreneurial spirit to make things happen, and because of the impact we create with our clients, investors, and organisations we work with globally. We are very proud of our teams globally who made this happen, our clients who trust us to support them to solve their challenges, and our stakeholders who help us make an impact. Thank You! #bestmanaged #impactthatmatters https://lnkd.in/d-8pzGvY
-
We are delighted to announce that Gyrus Capital has entered into a binding agreement to sell Intellera Consulting, an Italian consultancy firm operating in the public administration and healthcare sectors, to Accenture. Read more here: https://gyrus.info/3THh3HV
-